Abstract:Major depressive disorder (MDD) is a common disease with both affective and cognitive disorders. Alterations in metabolic systems of MDD patients have been reported, but the underlying mechanisms still remains unclear. We sought to identify abnormal metabolites in MDD by metabolomics and to explore the association between differential metabolites and neurocognitive dysfunction. Plasma samples from 53 MDD patients and 83 sex-, gender-, BMI-matched healthy controls (HCs) were collected. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) system was then used to detect metabolites in those samples. Two different algorithms were applied to identify differential metabolites in 2 groups. Of the 136 participants, 35 MDD patients and 48 HCs had completed spatial working memory test. Spearman rank correlation coefficient was applied to explore the relationship between differential metabolites and working memory in these 2 groups. The top 5 metabolites which were found in sparse partial least squares-discriminant analysis (sPLS-DA) model and random forest (RF) model were the same, and significant difference was found in 3 metabolites between MDD and HCs, namely, gamma-glutamyl leucine, leucine-enkephalin, and valeric acid. In addition, MDD patients had higher scores in spatial working memory (SWM) between errors and total errors than HCs. Valeric acid was positively correlated with working memory in MDD group. Gamma-glutamyl leucine, leucine-enkephalin, and valeric acid were preliminarily proven to be decreased in MDD patients. In addition, MDD patients performed worse in working memory than HCs. Dysfunction in working memory of MDD individuals was associated with valeric acid.

Increased Plasma Serine Concentrations in Depression

Plasma Concentrations of Excitatory Amino Acids, Serine, Glycine, Taurine and Histidine in Major Depression

Total Serum-Protein and Serum-Protein Fractions in Depression - Relationships to Depressive Symptoms and Glucocorticoid Activity

D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?

Increased Plasma Concentrations of Interleukin-6, Soluble Interleukin-6, Soluble Interleukin-2 and Transferrin Receptor in Major Depression.

Lower Serum L-Tryptophan Availability in Depression As a Marker of a More Generalized Disorder in Protein Metabolism

Plasma Soluble Interleukin-2-receptor in Depression: Relationships to Plasma Neopterin and Serum IL-2 Concentrations and HPA-axis Activity

Increased Serum Interleukin-1-receptor-antagonist Concentrations in Major Depression

Increased Neopterin and Interferon-Gamma Secretion and Lower Availability of L-tryptophan in Major Depression: Further Evidence for an Immune Response

Plasma metabolites were associated with spatial working memory in major depressive disorder

Alterations of plasma aspartic acid, glycine and asparagine levels in patients with major depressive disorder]

Serum uric acid a depression biomarker.

Plasma-soluble Interleukin-2 and Transferrin Receptor in Schizoprenia and Major Depression

Serum Levels of Excitatory Amino Acids, Serine, Glycine, Histidine, Threonine, Taurine, Alanine and Arginine in Treatment‐resistant Depression: Modulation by Treatment with Antidepressants and Prediction of Clinical Responsivity

Suppressant effects of dexamethasone on the availability of plasma L-tryptophan and tyrosine in healthy controls and in depressed patients.

Lower Degree of Esterification of Serum-Cholesterol in Depression - Relevance for Depression and Suicide Research

Increased Serum S100B Protein in Patients with Major Depression

Anthropometric and Biochemical Assessment of the Nutritional State in Depression: Evidence for Lower Visceral Protein Plasma Levels in Depression

Relationships Between Lower Plasma L-tryptophan Levels and Immune-Inflammatory Variables in Depression

An Analysis of Plasma Reveals Proteins in the Acute Phase Response Pathway to Be Candidate Diagnostic Biomarkers for Depression

The effects of glucocorticoids on the availability of L-tryptophan and tyrosine in the plasma of depressed patients